Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 1 month ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Renal Metabolic
Cardiometabolic Risk Factors and COVID-19 in the Asia-Pacific Region
Author(s): Ru Ying Fong , Annie Lee , Fei Gao , et al Added: 1 year ago

Vascular Disease and Surgery

COVID-19
GLP-1 RAs in T2D and Established or High-risk ASCVD
Author(s): Wanwarang Wongcharoen , Rungroj Krittayaphong , Wacin Buddhari , et al Added: 1 week ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Growth Differentiation Factor-15 in Chronic Heart Failure
Author(s): Yee Ling Cham , Alan Yean Yip Fong , Joshua Bui Kiong Chung , et al Added: 1 year ago

Heart Failure
Risk Prediction of CVD in the Asia-Pacific Region
Author(s): SCORE2 Asia-Pacific Writing Group , Steven HJ Hageman , Zijuan Huang , et al Added: 5 months ago

Demographic

Heart Failure
Undetectable hs-TnI Serves as a De-risking Marker
Author(s): Phattararuethai Sabkaewyod , Prin Vathesatogkit , Piyamitr Sritara Added: 6 months ago

Prevention & Chronic Conditions
MACE Risk Prediction by Machine Learning
Author(s): Fang He , John H Page , Jesisca Tandi , et al Added: 1 year ago

MI/ACS
Hospital Frailty Risk Score in Heart Failure
Author(s): Zhenwei Teo , Ying Zi Oh , Weiliang Huang , et al Added: 11 months ago

Guidelines & Statements

Heart Failure
EASD 23: Epidemiologic Trends & Disparities in Diabetes Risk Among LGBTQ+ Population
Author(s): Carl Streed Added: 1 year ago
EASD 2023 – Dr Carl G Streed (Boston University School of Medicine, US) joins us to summarise healthcare disparities among the LGBTQ+ population.In this interview, Dr Streed discusses the available evidence and explains the minority stress model. This model suggests that experiences of discrimination and stress contribute to worse health outcomes in the LGBTQ community. This can lead to mental… View more

Demographic

Prevention & Chronic Conditions
ACC 2025: EVOLUT Low Risk 5Y Outcomes
Author(s): Michael J Reardon Added: 1 month ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical… View more

Intervention